| 1. Goldberg YP, MacFarlane J, MacDonald ML, Thompson J, Dube MP, Mattice M, Fraser R, Young C, Hossain S, Pape T, Payne B, Radomski C, Donaldson G, Ives E, Cox J, Younghusband HB, Green R, Duff A, Boltshauser E, Grinspan GA, Dimon JH, Sibley BG, Andria G, Toscano E, Kerdraon J, Bowsher D, Pimstone SN, Samuels ME, Sherrington R, Hayden MR. (2007) Loss-of-function mutations in the Nav1.7 gene underlie congenital indifference to pain in multiple human populations.. Clin Genet, 71 (4): (311-9). [PMID:17470132] |
| 2. Cox JJ, Reimann F, Nicholas AK, Thornton G, Roberts E, Springell K, Karbani G, Jafri H, Mannan J, Raashid Y et al.. (2006) An SCN9A channelopathy causes congenital inability to experience pain.. Nature, 444 (7121): (894-8). [PMID:17167479] |
| 3. Bagal SK, Chapman ML, Marron BE, Prime R, Storer RI, Swain NA. (2014) Recent progress in sodium channel modulators for pain.. Bioorg Med Chem Lett, 24 (16): (3690-9). [PMID:25060923] |
| 4. Gingras J, Smith S, Matson DJ, Johnson D, Nye K, Couture L, Feric E, Yin R, Moyer BD, Peterson ML et al.. (2014) Global Nav1.7 knockout mice recapitulate the phenotype of human congenital indifference to pain.. PLoS ONE, 9 (9): (e105895). [PMID:25188265] |
| 5. McKerrall SJ, Sutherlin DP. (2018) Nav1.7 inhibitors for the treatment of chronic pain.. Bioorg Med Chem Lett, 28 (19): (3141-3149). [PMID:30139550] |
| 6. Shields SD, Deng L, Reese RM, Dourado M, Tao J, Foreman O, Chang JH, Hackos DH. (2018) Insensitivity to Pain upon Adult-Onset Deletion of Nav1.7 or Its Blockade with Selective Inhibitors.. J Neurosci, 38 (47): (10180-10201). [PMID:30301756] |
| 7. McKerrall SJ, Nguyen T, Lai KW, Bergeron P, Deng L, DiPasquale A, Chang JH, Chen J, Chernov-Rogan T, Hackos DH et al.. (2019) Structure- and Ligand-Based Discovery of Chromane Arylsulfonamide Nav1.7 Inhibitors for the Treatment of Chronic Pain.. J Med Chem, 62 (8): (4091-4109). [PMID:30943032] |
